What's new in paediatric SLE?

Area of Science:

• Pediatric Rheumatology
• Cardiovascular Disease in Autoimmunity

Background:

• Systemic lupus erythematosus (SLE) affects 15-20% of children under 16, often presenting with greater severity and kidney involvement.
• While childhood SLE mortality has decreased due to earlier diagnosis and better care, long-term complications are emerging.
• Treatment protocols for childhood lupus nephritis are primarily based on adult data, lacking specific pediatric clinical trial evidence.

Purpose of the Study:

• To review the challenges and advancements in managing childhood-onset SLE.
• To highlight the significant risk of early-onset atherosclerosis and myocardial ischemia in young SLE patients.
• To emphasize the need for pediatric-specific research on SLE pathogenesis and preventative strategies.

Main Methods:

• Review of current literature on childhood-onset SLE.
• Analysis of treatment strategies adapted from adult SLE management.
• Examination of secondary complications, particularly atherosclerosis, in pediatric SLE cohorts.

Main Results:

• Childhood SLE frequently involves critical organs and carries a higher risk of severity.
• Improved survival has revealed increased incidence of early atherosclerosis and myocardial ischemia in young adults with childhood-onset SLE.
• Disease and treatment factors contribute to atherogenesis in SLE patients.

Conclusions:

• There is a critical need for pediatric-specific clinical trials to establish treatment efficacy and safety in childhood SLE.
• Preventative strategies against atherosclerosis are crucial for improving long-term outcomes in individuals with childhood-onset SLE.
• Further research into the pathogenesis of SLE and its cardiovascular complications in children is essential.